Bank Pictet & Cie Europe AG Buys 21,470 Shares of Zoetis Inc. (NYSE:ZTS)

Bank Pictet & Cie Europe AG raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 419,530 shares of the company’s stock after acquiring an additional 21,470 shares during the quarter. Zoetis makes up 1.5% of Bank Pictet & Cie Europe AG’s portfolio, making the stock its 18th largest holding. Bank Pictet & Cie Europe AG owned about 0.09% of Zoetis worth $68,354,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC increased its stake in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

Zoetis stock opened at $157.54 on Friday. The firm has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The business has a 50-day moving average of $168.89 and a 200-day moving average of $178.98. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. On average, equities analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis’s payout ratio is currently 37.59%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. Piper Sandler lowered their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.